Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinal pigment epithelial (RPE) cell loss refers to the reduction in number or function of RPE cells, a monolayer of pigmented cells located between the neural retina and the choroid. These cells are essential for retinal health, supporting photoreceptor survival, phagocytosing shed photoreceptor outer segments (POS), maintaining the blood-retina barrier, and regulating nutrient/waste exchange. Loss or dysfunction of RPE cells is implicated in several degenerative retinal diseases, most notably age-related macular degeneration (AMD), leading to secondary death of overlying photoreceptors and vision loss. Key mechanisms contributing to RPE cell loss include aging, oxidative stress, inflammation, and genetic factors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinal Pigment Epithelial Cell Loss.